Ultragenyx Pharmaceutical, Inc. is a clinical-stage biotechnology company that is focused on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare diseases, with an initial focus on serious, debilitating metabolic genetic diseases. It intends to build therapies to address these clinically underserved diseases. The company was founded by Emil D. Kakkis on April 22, 2010 and is headquartered in Novato, CA.
